Welcome to our dedicated page for Rcm Tech SEC filings (Ticker: RCMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RCM Technologies, Inc. (RCMT) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. RCM, a Nevada corporation whose common stock trades on the Nasdaq Capital Market, submits annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and proxy materials such as the definitive proxy statement on Schedule 14A.
In its periodic reports, RCM presents consolidated financial statements and segment information for its Specialty Health Care, Engineering and Life Sciences, Data and Solutions businesses. These filings detail revenue, cost of services, gross profit, operating income, net income, balance sheet data and cash flows, along with discussions of risk factors and management’s analysis of results. The company also discloses its use of non-GAAP measures—Adjusted operating income, EBITDA, Adjusted EBITDA, Adjusted net income and Adjusted diluted net earnings per share—and provides reconciliations to the most directly comparable GAAP figures.
Current reports on Form 8-K for RCM include items such as quarterly earnings press releases furnished under Item 2.02 and changes in the company’s independent registered public accounting firm under Item 4.01. One filing describes the dismissal of WithumSmith+Brown, PC and the engagement of EisnerAmper LLP to audit the company’s financial statements and internal control over financial reporting for a specified fiscal year, as well as the remediation of a previously reported material weakness in certain IT general controls.
The company’s definitive proxy statement (DEF 14A) outlines governance and shareholder matters, including the election of directors, approval of an omnibus equity compensation plan, ratification of the independent accountants, and advisory votes on executive compensation and the frequency of such votes. It also explains voting procedures, record dates, quorum requirements and how stockholders can attend and vote at the virtual annual meeting.
On this page, Stock Titan pairs RCM’s SEC filings with AI-powered summaries to help readers quickly understand the key points in lengthy documents. Filings are updated as they are made available on EDGAR, allowing investors to review RCMT’s financial reporting, auditor changes, executive compensation disclosures and other regulatory information in one place, with plain-language explanations of complex sections.
RCM Technologies filed its definitive proxy for the 2025 Annual Meeting, to be held virtually on December 18, 2025 at 4:00 p.m. ET. Stockholders of record as of October 22, 2025, may vote; there were 7,410,510 shares of common stock outstanding on the record date.
Key items include the election of four directors and approval of the 2025 Omnibus Equity Compensation Plan authorizing up to 1,000,000 shares. The plan features a general one‑year minimum vesting schedule (with limited exceptions), a $100,000 annual equity limit for non‑employee directors, and eligibility for employees, directors, and consultants. The filing outlines standard voting/quorum procedures and virtual attendance steps. Reported beneficial owners include Ben Andrews at 535,048 shares (7.2%) and Renaissance Technologies LLC at 485,473 shares (6.6%). The Summary Compensation Table shows 2024 total compensation of $7,731,221 for Executive Chairman & President Bradley S. Vizi, with details on PSU/RSU grants and outcomes.
RCM Technologies (RCMT) reported Q3 2025 results with revenue of $70.3 million and diluted EPS of $0.30. Operating income was $3.9 million. For the first thirty‑nine weeks, revenue reached $232.9 million and diluted EPS was $1.34, as operating income rose to $17.1 million.
Growth was led by Engineering (Q3 revenue $31.4 million) and Specialty Health Care ($30.0 million), while Life Sciences, Data & Solutions posted $8.9 million. Gross profit for the quarter was $19.4 million on cost of services of $50.9 million. Two customers represented 19.6% and 13.2% of year‑to‑date revenue, both within Specialty Health Care.
Cash was $1.3 million, borrowings under the line of credit were $31.5 million, and letters of credit outstanding were $13.1 million. The revolving credit facility was amended to $65.0 million with maturity on December 3, 2029. The company repurchased 301,640 shares at an average price of $16.89 during the first thirty‑nine weeks, with $37.1 million remaining under the authorization. Common shares outstanding were 7,410,510 as of November 5, 2025.
RCM Technologies, Inc. filed a current report to note that it has issued a press release covering its financial results for the thirteen and thirty-nine weeks ended September 27, 2025. The press release is furnished as Exhibit 99 to the report and contains the detailed figures and discussion of operating performance for those periods.
The company specifies that the information in the results section, including the exhibit, is being furnished rather than filed under securities laws, which affects how it is treated for certain legal and liability purposes. The report also confirms there were no acquired-business financial statements, no pro forma financial information, and no shell company transactions included.
Bradley S. Vizi, Executive Chairman & President of RCM Technologies, Inc. (RCMT), reported three sales of the issuer's common stock on 09/22/2025–09/24/2025 under a nondiscretionary Rule 10b5-1 plan established 12/07/2023. Total reported disposition was 1,258 shares at a weighted average price of approximately $27.50 per share. After these transactions the reporting person beneficially owned 1,511,333 shares directly. The filing discloses the sales were pre-arranged and the filer will provide specific per-price breakdowns on request.
Bradley S. Vizi, Executive Chairman and President of RCM Technologies (RCMT), reported routine insider sales under a pre-established Rule 10b5-1 plan. The Form 4 discloses three non-discretionary sales executed on 09/17/2025, 09/18/2025 and 09/19/2025 for aggregate reductions from his holdings: after the 09/17 sale he beneficially owned 1,519,036 shares, after 09/18 he owned 1,516,416 shares, and after 09/19 he owned 1,512,591 shares. The reported sale prices are reported as weighted averages in the $27.50–$27.595 ranges. The filing is a disclosure of executed sales under a December 7, 2023 plan and does not provide additional commentary.
RCM Technologies insider Bradley Vizi, Executive Chairman & President, reported three routine sales of common stock in early September 2025 under a pre-established Rule 10b5-1 trading plan. The filings show dispositions of 4,508 shares on 09/05/2025 at a weighted average price near $27.50, 3,961 shares on 09/08/2025 at a weighted average near $27.51, and 4 shares on 09/09/2025 at $27.50. Following these transactions, Mr. Vizi beneficially owned 1,522,805 shares (direct). The Form 4 notes the sales were nondiscretionary under a plan established December 7, 2023.
Bradley S. Vizi, who serves as Executive Chairman & President and is a director and 10% owner of RCM Technologies, Inc. (RCMT), reported a sale of 673 shares of the issuer's common stock on 08/29/2025 at a reported price of $27.50 per share. The sale was made pursuant to a nondiscretionary plan established by the reporting person on December 7, 2023 intended to satisfy Rule 10b5-1 affirmative defense conditions. Following the reported transaction, the reporting person beneficially owns 1,531,278 shares in a direct capacity. The Form 4 is signed by Bradley S. Vizi dated 09/03/2025.
Bradley S. Vizi, Executive Chairman & President of RCM Technologies, Inc. (RCMT), reported a non-derivative sale of common stock on 08/26/2025. The Form 4 shows a sale of 7,289 shares at $27.51 per share executed under a nondiscretionary plan established on December 7, 2023 to satisfy Rule 10b5-1 requirements. After the sale, the reporting person beneficially owned 1,531,951 shares. The filing identifies Mr. Vizi as a director and a greater-than-10% owner. No derivative transactions are reported on this form.
Michael Saks, Division President, Healthcare Services at RCM Technologies, reported a sale of 5,000 shares of RCM Technologies common stock on 08/26/2025 at a reported price of $27.50 per share. After the transaction, the filing shows the reporting person beneficially owns 109,547 shares. The filing also notes 393 shares were acquired under the issuer's Employee Stock Purchase Plan since the most recent Section 16 filing.
The sale is reported as a nondiscretionary transaction executed under a plan established to satisfy Rule 10b5-1 requirements, indicating the disposition followed a prearranged plan rather than an ad hoc decision. The Form 4 lists the reporting person as an officer of the company and is filed by one reporting person.
RCM Technologies (RCMT) submitted a Form 144 reporting a proposed sale of 260,856 shares of common stock through Baird on the NASDAQ with an aggregate market value of $6,850,000. The filing lists 7,410,510 shares outstanding, and the securities to be sold were acquired as restricted share vesting under equity compensation on 01/15/2021 (125,000), 01/03/2023 (125,000) and 01/16/2023 (50,000). The filer reports no sales in the past three months and includes the standard representation that they are not aware of undisclosed material adverse information.
FAQ
What is the current stock price of Rcm Tech (RCMT)?
What is the market cap of Rcm Tech (RCMT)?
